A Gupta1, R J Young1, A I Holodny1, A B Lassman1, S Karimi1, S Sood1, Z Zhang1, Q Mo1, P H Gutin1. 1. Department of Radiology (A.G., R.J.Y., S.K., S.S., A.I.H.), Brain Tumor Center (R.J.Y., S.K., P.H.G., A.I.H., A.B.L.), Departments of Neurosurgery (P.H.G.), Epidemiology and Biostatistics (Z.Z., Q.M.), and Neurology (A.B.L.), Memorial Sloan-Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND AND PURPOSE: Most response criteria for patients with glioblastoma rely on increases in the contrast enhancing abnormality to determine tumor progression. Our aim was to determine retrospectively in patients with glioblastoma whether diffusion restriction can predict the development of new enhancing mass lesions. MATERIALS AND METHODS: We reviewed the brain MR imaging scans (including DWI and ADC maps) of 208 patients with glioblastoma. Patients with restricted diffusion in or adjacent to the tumor were identified, with further analysis only performed on those patients with low-ADC lesions without enhancement. These patients were followed to determine if new concordant enhancement developed at the site of the low-ADC lesion. A Wilcoxon signed rank test, competing risk analysis, and Kaplan-Meier curves were used to compare the mean drop in ADC values, assess enhancement-free survival, and determine overall survival, respectively. RESULTS: In 67 of the 208 patients (32.2%), visibly detectable restricted diffusion was seen during treatment. The study cohort was formed by the 27 patients with low-ADC lesions and no corresponding enhancement. Twenty-three (85.2%) patients developed gadolinium-enhancing tumor at the site of restricted diffusion a median of 3.0 months later (95% CI, 2.6-4.1 months). The mean decrease in ADC was 22.9% from baseline (P < .001). The 3-month enhancement-free survival probability was 0.481 (95% CI, 0.288-0.675). The 12-month overall survival probability was 0.521 (95% CI, 0.345-0.788). Restricted diffusion predicted enhancement regardless of antiangiogenic therapy with bevacizumab. CONCLUSIONS: In a subset of patients with glioblastoma, development of a new focus of restricted diffusion during treatment may precede the development of new enhancing tumor.
BACKGROUND AND PURPOSE: Most response criteria for patients with glioblastoma rely on increases in the contrast enhancing abnormality to determine tumor progression. Our aim was to determine retrospectively in patients with glioblastoma whether diffusion restriction can predict the development of new enhancing mass lesions. MATERIALS AND METHODS: We reviewed the brain MR imaging scans (including DWI and ADC maps) of 208 patients with glioblastoma. Patients with restricted diffusion in or adjacent to the tumor were identified, with further analysis only performed on those patients with low-ADC lesions without enhancement. These patients were followed to determine if new concordant enhancement developed at the site of the low-ADC lesion. A Wilcoxon signed rank test, competing risk analysis, and Kaplan-Meier curves were used to compare the mean drop in ADC values, assess enhancement-free survival, and determine overall survival, respectively. RESULTS: In 67 of the 208 patients (32.2%), visibly detectable restricted diffusion was seen during treatment. The study cohort was formed by the 27 patients with low-ADC lesions and no corresponding enhancement. Twenty-three (85.2%) patients developed gadolinium-enhancing tumor at the site of restricted diffusion a median of 3.0 months later (95% CI, 2.6-4.1 months). The mean decrease in ADC was 22.9% from baseline (P < .001). The 3-month enhancement-free survival probability was 0.481 (95% CI, 0.288-0.675). The 12-month overall survival probability was 0.521 (95% CI, 0.345-0.788). Restricted diffusion predicted enhancement regardless of antiangiogenic therapy with bevacizumab. CONCLUSIONS: In a subset of patients with glioblastoma, development of a new focus of restricted diffusion during treatment may precede the development of new enhancing tumor.
Authors: T Sugahara; Y Korogi; M Kochi; I Ikushima; Y Shigematu; T Hirai; T Okuda; L Liang; Y Ge; Y Komohara; Y Ushio; M Takahashi Journal: J Magn Reson Imaging Date: 1999-01 Impact factor: 4.813
Authors: Meng Law; Sarah Oh; Glyn Johnson; James S Babb; David Zagzag; John Golfinos; Patrick J Kelly Journal: Neurosurgery Date: 2006-06 Impact factor: 4.654
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: John R Hesselink; Matthew J Barkovich; Tyler M Seibert; Nikdokht Farid; Karra A Muller; Kevin T Murphy; Santosh Kesari Journal: CNS Oncol Date: 2014
Authors: S Mong; B M Ellingson; P L Nghiemphu; H J Kim; L Mirsadraei; A Lai; W Yong; T M Zaw; T F Cloughesy; W B Pope Journal: AJNR Am J Neuroradiol Date: 2012-04-26 Impact factor: 3.825
Authors: Andrew Elson; Eric Paulson; Joseph Bovi; Malika Siker; Chris Schultz; Peter S Laviolette Journal: J Neurooncol Date: 2015-04-17 Impact factor: 4.130
Authors: H S Nguyen; N Milbach; S L Hurrell; E Cochran; J Connelly; J A Bovi; C J Schultz; W M Mueller; S D Rand; K M Schmainda; P S LaViolette Journal: AJNR Am J Neuroradiol Date: 2016-08-04 Impact factor: 3.825
Authors: Lei Qin; Xiang Li; Amanda Stroiney; Jinrong Qu; Jeffrey Helgager; David A Reardon; Geoffrey S Young Journal: Neuroradiology Date: 2017-01-09 Impact factor: 2.804
Authors: Ramon F Barajas; Nicholas A Butowski; Joanna J Phillips; Manish K Aghi; Mitchel S Berger; Susan M Chang; Soonmee Cha Journal: Acad Radiol Date: 2016-07-18 Impact factor: 3.173
Authors: Stephen F Futterer; Alexander J Nemeth; Sean A Grimm; Ann B Ragin; James P Chandler; Kenji Muro; Maryanne H Marymont; Jeffrey J Raizer Journal: J Neurooncol Date: 2014-02-28 Impact factor: 4.130
Authors: S Rose; M Fay; P Thomas; P Bourgeat; N Dowson; O Salvado; Y Gal; A Coulthard; S Crozier Journal: AJNR Am J Neuroradiol Date: 2012-10-18 Impact factor: 3.825